Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy

Inclusion Criteria: * Men or women \> 30 years old * Subject is able and willing to comply with study procedures, and is able to give signed and dated consent * Subject meets criteria for diagnosis of Diabetes Mellitus Type 1 or 2, active Charcot neuroarthropathy, and peripheral neuropathy * Subjects with serum calcium or albumin-adjusted serum calcium ≥2.0 mmol/L (8.0mg/dL) Exclusion Criteria: * Unable to provide signed and dated consent. * Charcot neuroarthropathy of the ipsilateral lower extremity, diagnosed over 1 month prior. * Prior foot or ankle surgery of the ipsilateral lower extremity. * Prior amputation at any level of either lower extremity. * Prior foot or ankle fracture of the ipsilateral lower extremity unrelated to the current acute CN episode. * Currently has any of the following: 1. Infection 2. Foot ulceration 3. Hypocalcemia 4. Creatinine clearance less than 30 mL/min or on dialysis 5. Pre-existing disturbance of mineral metabolism (e.g., hypoparathyroidism unstable on therapy, thyroid or parathyroid surgery, vitamin D deficiency, malabsorption syndromes, excision of small intestine, history of diseases affecting bone metabolism) that has not been effectively corrected or treated. * Have undergone revascularization procedures of the lower extremities. * Female subjects who are pregnant or planning to breastfeed should not participate in this study. * Determined to have poor oral hygiene after dental screening or are at increased risk for developing osteonecrosis of the jaw. * History of osteonecrosis of the jaw. * History of tooth extraction or other dental surgery within the prior 6 months. * Invasive dental work planned in the next 2 years. * Have a known hypersensitivity to Prolia. * Known use of a bone active medication within the 6 months prior to enrollment. * Liver disease, defined as AST \> 2.0x ULN, ALT \> 2.0x ULN, TBL \> 1.5x ULN. * Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma)